The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events-Reference-Cited by-同舟云学术

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events

Published:2015-09-29 Issue: Volume:9 Page:
ISSN:1662-453X
Container-title:Frontiers in Neuroscience
language:
Short-container-title:Front. Neurosci.

Author:

Blennow Kaj,Zetterberg Henrik

Publisher

Frontiers Media SA

Subject

General Neuroscience

Reference82 articles.

1. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease;Albert;Alzheimer's Demen.,2011

2. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease;Andreasen;Archiv. Neurol,1999a

3. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample;Andreasen;Neurology,1999b

4. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment;Andreasen;Neurosci. Lett.,1999

5. Clinical chemistry and laboratory medicine: an appreciation;Beastall;Clin. Chem. Lab. Med,2013

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal post-shunt outcomes in idiopathic normal pressure hydrocephalus with and without comorbid Alzheimer’s disease;Journal of the International Neuropsychological Society;2022-12-14

2. Blood-based biomarkers in Alzheimer’s disease: a mini-review;Metabolic Brain Disease;2022-11-07

3. Sagacious confucius’ pillow elixir ameliorates Dgalactose induced cognitive injury in mice via estrogenic effects and synaptic plasticity;Frontiers in Pharmacology;2022-09-28

4. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer’s Disease?;Molecules;2022-08-09

5. Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers;Arquivos de Neuro-Psiquiatria;2022-05